| March 2 |
Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology |
| March 2 |
Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound |
| March 2 |
Astellas and XenoPort Announce Positive Results from Phase 2 Trial of ASP8825/XP13512 in Japan for Restless Legs Syndrome |
| March 2 |
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC) |
| March 2 |
Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba |
| March 2 |
NanoBio to Announce Key Clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009 |
| March 2 |
Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory and Anti-Fungal Candidates, AN2728, AN2898 and AN2718, at the American Academy of Dermatology Annual Meeting |
| March 2 |
New head-to-head data published in The Lancet: Prasugrel reduces cardiovascular event risk in high-risk heart attack patients when compared to clopidogrel |
| March 3 |
Drug Resistant Influenza A Virus Potentially Serious to High-Risk Patients |
| March 3 |
Inactivated Flu Vaccine Associated With Fewer Medical Visits for Respiratory Illness Than Intranasal Vaccine |
| March 3 |
Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures |
| March 3 |
Rituximab Reduces Kidney Inflammation in Patients with Lupus |
| March 4 |
EPIX Pharmaceuticals to Present Alzheimer's Disease Data at the American Society for Experimental NeuroTherapeutics Annual Meeting |
| March 4 |
Anacor Announces Positive Results From Phase 1 Trial of AN2718 |
| March 5 |
Opexa Provides Key Quality of Life Data on Tovaxin for Multiple Sclerosis |
| March 5 |
Access Pharmaceuticals Announces Positive ProLindac Phase 2 Ovarian Cancer Clinical Trial Results |
| March 5 |
Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting |
| March 5 |
Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant |
| March 5 |
CV Therapeutics Reports Phase 1 Data Showing Proof of Concept for CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases |
| March 5 |
Cypher Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Six-Year Randomized Clinical Trial |
| March 5 |
The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection |
| March 6 |
Anacor Announces Positive Results from Phase 1 Safety Trial of AN2898 for Psoriasis and Atopic Dermatitis |
| March 6 |
Basilea Pharmaceutica Ltd. (CH) - Basilea presents research data on a novel antibiotic at the Anti-Infectives Partnering & Deal-Making Summit |
| March 6 |
Sepracor Reports Preliminary Phase II Study Results for SEP-225441 for the Treatment of Generalized Anxiety Disorder |
| March 6 |
Peplin's Positive Phase IIb AK Trial Result Details |
| March 6 |
Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex Spray Followed by Vectical Ointment in Managing Plaque Psoriasis |
| March 9 |
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon in Chronic Hepatitis C |
| March 9 |
AndroScience Corporation Announces Phase 2a Study Results on ASC-J9 for the Treatment of Acne |
| March 9 |
Human Genome Sciences to Sponsor Conference Call |
| March 10 |
ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009 |
| March 10 |
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia |
| March 10 |
Bayhill Therapeutics to Present Phase II Follow-up Data on BHT-3009 for Treatment of Multiple Sclerosis |
| March 10 |
Biothera to Release Cancer Data at 2009 ASCO Meeting |
| March 10 |
Promising Three-year Data: Saving Limbs With Drug-Eluting Stents |
| March 10 |
Generex Biotechnology Announces Successful Phase III Study Data for Generex Oral-lyn |
| March 10 |
New Insights into the Mechanism of Action of Antipsychotic Drugs |
| March 11 |
Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data |
| March 11 |
GW Reports Positive Outcome of Sativex Phase III Multiple Scelerosis Study |
| March 11 |
Clinical Data, Inc. Announces Publication of Results from First Phase III Study of Vilazodone in Treatment of Major Depressive Disorder |
| March 11 |
Two Publications Highlight Vilazodone as Strong Potential Treatment for Depression |
| March 12 |
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint |
| March 12 |
Researchers Investigate Rituximab Potential |
| March 12 |
Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early |
| March 12 |
QLT Announces Completion of Phase Ia Safety Trial of its Synthetic Retinoid Product |
| March 12 |
Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study |
| March 12 |
pSivida Corp Reports Favorable 12-Month Interim Safety and Efficacy Results from Iluvien Human PK Study |
| March 13 |
Arimidex offers women greater protection against HR+ early breast cancer returning in the 1st 2 yrs |
| March 13 |
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent |
| March 13 |
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study |
| March 13 |
YM BioSciences Announces Nimotuzumab Presentations to be Made at the 100th Annual Meeting of the American Association for Cancer Research and European Society for Medical Oncology |
| March 16 |
Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347 |
| March 16 |
Oncolytics Biotech Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting |
| March 16 |
Clavis Pharma ASA (NO) - Clavis Pharma Announces Positive Elacytarabine Phase II Results |
| March 16 |
New, Published Gelnique Data Show Efficacy, Convenience and Excellent Tolerability |
| March 16 |
C1-Esterase Inhibitor Concentrate Rapidly Relieves Acute Swelling Attacks Across All Body Sites in Patients with Hereditary Angioedema, According to Study |
| March 16 |
Avexa Reports Positive 96 Week Data for HIV Drug Apricitabine (ATC) |
| March 16 |
CyDex Pharmaceuticals Presents Phase 2 Clinical Trial Results for Captisol-Enabled Budesonide/Azelastine Combination Solution Nasal Spray at American Academy of Allergy Asthma and Immunology (AAAAI) Meeting |
| March 16 |
CytRx's Arimoclomol Demonstrates Statistically Significant Neurorestorative Results in a Preclinical Embolic Stroke Trial |
| March 16 |
DURECT Reports Positive Phase IIb Data from TRANSDUR-Sufentanil Clinical Program |
| March 16 |
Adult Stem Cell Study Demonstrates Improved Quality of Life for Patients Suffering from Spinal Cord Injury |
| March 16 |
New, published data demonstrate effectiveness/excellent tolerability for first topical OAB treatment |
| March 16 |
Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results |
| March 16 |
Unigene Reports Positive PTH Clinical Study Results |
| March 16 |
Data Presented at AAAAI Reinforce Baxter's Commitment to Making GAMMAGARD LIQUID Therapy More Convenient |
| March 17 |
Cytheris Announces Publication of IL-7 HIV Data in The Journal of Clinical Investigation |
| March 17 |
Cephalon Announces Positive Results From a Phase Two Study of Nuvigil in Bipolar Depression |
| March 17 |
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research |
| March 17 |
Study Demonstrates That QVAR is More Likely to Achieve Successful Asthma Control with Less Exacerbations |
| March 18 |
BEMA Buprenorphine to Proceed to Phase 2 Following Favorable Initial Study Results |
| March 18 |
EPIX Pharmaceuticals to Present Preclinical Data at the 237th American Chemical Society National Meeting and Exposition |
| March 18 |
ULURU Inc. to Present Altrazeal Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 |
| March 18 |
Medication Does Not Appear to Reduce Progression of Atherosclerosis |
| March 18 |
Narcolepsy Drug Being Used to Improve Cognitive Performance Affects Brain Dopamine Activity, Suggesting Potential For Abuse and Dependence |
| March 19 |
SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin |
| March 19 |
Cytochroma announces new findings regarding the role of CYP24 in chronic kidney disease |
| March 19 |
Glivec Substantially Reduces Risk Of Cancer Returning In Patients With Life-Threatening Gastrointestinal Stromal Tumors, The Lancet Reports |
| March 19 |
Gleevec Substantially Reduces Risk of Cancer Returning in Patients with Life-threatening Gastrointestinal Stromal Tumors (GIST), The Lancet Reports |
| March 19 |
Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) |
| March 19 |
AngioChem's ANG1005 Shows Promise In the Treatment of Brain Cancers |
| March 19 |
ImVisioN Therapeutics Reports Positive Phase I Clinical Results for Treatment of Cat Dander Allergy |
| March 20 |
Publication Highlights Potential of Santhera's Oral MC4-Receptor Antagonist Program for Treatment of Cancer Cachexia |
| March 20 |
Palonosetron Warrants Adequate Caloric Intake In Oncology Patients Receiving High Emetogenic Chemotherapy |
| March 20 |
Oncolytics Biotech Inc. Collaborators Update Combination Reolysin and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting |
| March 20 |
Oncolytics Biotech Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination Reolysin and Paclitaxel/Carboplatin Trial |
| March 23 |
Neuromed Announces Exalgo (hydromorphone HCl) Extended-Release Tab... |
| March 23 |
Advaxis Updates Phase I Trial Survival Data: 23% of Patients Still Surviving after 2+ Years |
| March 23 |
Metabasis Therapeutics Announces Positive Results in a Clinical Trial of MB07803 in Patients with Poorly Controlled Type 2 Diabetes |
| March 24 |
Vical's Allovectin-7 Phase 3 Trial Receives Positive Review From Safety Monitoring Board |
| March 24 |
Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity |
| March 24 |
Endocyte Announces Positive Interim Results from Phase II Clinical Trial of EC145 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) |
| March 25 |
Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients |
| March 25 |
Orexo announces Phase IIa data on OX914 in rhinitis |
| March 25 |
Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA) |
| March 25 |
News Alert: HemCon Announces Improved Results from Live Nail Infection Study |
| March 26 |
Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows |
| March 26 |
Celtic Pharma - Successful Outcome of Phase II Trial for Topical Treatment of Onychomycosis |
| March 26 |
Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain |
| March 26 |
Positive Phase 3 uveitis trial results for voclosporin reported by Isotechnika's partner Lux Biosciences |
| March 26 |
Reata Completes Financing and Expands Team to Capture Opportunity Created by Encouraging Clinical Data in Chronic Kidney Disease |
| March 26 |
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events |
| March 26 |
Lux Biosciences Reports Positive Results from LUMINATE Phase 3 Program of LX211 (LUVENIQ) in Uveitis |
| March 26 |
Positive Results from Neurotech's NT-501 Phase 2 Dry AMD (Geographic Atrophy) Study Demonstrate Proof of Concept |
| March 26 |
RegeneRx Reports Phase II Venous Stasis Trial Results |
| March 26 |
Hythiam Announces Results of Two Double-Blind, Placebo-Controlled Studies on Impact of Prometa Treatment Program for Alcohol Dependence |
| March 26 |
VGX Pharmaceuticals' Oral Anti-Inflammatory Drug Safe in Phase I Study |
| March 26 |
Boston Scientific Announces Schedule For ACC 2009 |
| March 27 |
Affymax Reports Phase 2 Sub-Analysis of Hematide in Hemodialysis Patients |
| March 27 |
Dapagliflozin Clinical Trial Results Indicate Improvement In Key Glycemic Measures In Treatment-Naïve Type 2 Diabetes Patients |
| March 27 |
Medgenics' Phase I/II Clinical Trial Now Shows Epodure Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients |
| March 30 |
Crestor Reduced Risk of Blood Clots in the Veins |
| March 30 |
Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research |
| March 30 |
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal for Fabry Disease at ACMG 2009 Annual Meeting |
| March 30 |
Abbott's Market-Leading XIENCE V Shows Increasing Clinical Advantages Over TAXUS Express2/TAXUS Liberte Between Two and Three Years |
| March 30 |
Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints |
| March 30 |
New Data for Abbott's TRILIPIX (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management |
| March 30 |
Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results |
| March 30 |
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session |
| March 30 |
SYNTAX Analysis Finds Treatment With TAXUS Express2 Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease |
| March 30 |
Celsion Announces Promising ThermoDox Clinical Results in Primary Liver Cancer Were Published in Expert Opinion |
| March 30 |
AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents |
| March 30 |
Data from Gencaro Phase 3 Best Trial Presented at the American College of Cardiology 58(th) Annual Scientific Session |
| March 30 |
Gentium Announces Preliminary Results from a Phase 2/3 European Pediatric Prevention Trial for Veno-Occlusive Disease at the European Group for Blood and Marrow Transplantation Annual Meeting |
| March 30 |
Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders |
| March 30 |
Amorcyte Presents Results of Stem Cell Study at ACC on Improved Blood Circulation After Severe Heart Attack |
| March 30 |
Pronova BioPharma ASA (NO) - Findings in the OMEGA study presented |
| March 30 |
Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms |
| March 30 |
Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure |
| March 30 |
New Lantheus Study Finds Significant Survival Benefit for Critically Ill Patients Undergoing Contrast-Enhanced Echocardiography |
| March 30 |
Comparative Analysis of Four Beta Blocker Trials Presented at the American College of Cardiology 58(th) Annual Scientific Session |
| March 30 |
Combination Adult Stem Cell Therapy Improves Severe Limb Ischemia |
| March 30 |
Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing Human HIV Antibodies and Change of Company Name to Theraclone Sciences, Inc. |
| March 30 |
SARcode Announces Results of Phase 1 Trial of SAR 1118 Ophthalmic Solution in Healthy Adult Subjects |
| March 30 |
Schering-Plough Announces Results of the Early ACS Trial |
| March 30 |
Intensive Lipitor Therapy Provided Sustained Risk Reduction Of Cardiovascular Events In Older Patients With Heart Disease |
| March 31 |
Karo Bio Reports Positive Results For Kb3305 In Diabetes Patients |
| March 31 |
New analyses of phase 3 data for NicOx’ naproxcinod presented at the American College of Cardiology (ACC) Annual Meeting |
| March 31 |
Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix (Varenicline) Compared With Placebo |
| March 31 |
Plavix Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral Anticoagulants |
| March 31 |
Zosano Pharma, Inc. to Present Positive Phase 2 Results of Its Transdermal Patch for Osteoporosis |
| March 31 |
Novel PET Myocardial Perfusion Imaging Tracer Data Presented |
| March 31 |
Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study |
| March 31 |
New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery |
| March 31 |
VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009 |
| March 31 |
New Data Presented at ACC.09 Shows Benefit of Cardiac Resynchronization Therapy in Mildly Symptomatic Heart Failure Patients |
